China's Prescription for Affordable Medicines

The Chinese government made a bold move to bring down the cost of essential medicines by introducing the National Volume-Based Procurement policy. This policy leverages economies of scale to make medicines more affordable for its citizens. One of the first medicines to benefit from this policy was montelukast sodium, a widely prescribed treatment for respiratory diseases.

To understand the impact of this policy, researchers analyzed national procurement data from the National Healthcare Security Administration. They used a special statistical model to correct for any patterns in the data and then compared the numbers before and after the policy was implemented.

The results were impressive. The policy led to a significant drop in the cost of montelukast sodium, making it more affordable for patients. But what's even more interesting is that the total amount of the medicine being procured didn't change much. This suggests that doctors were prescribing the medicine based on the patient's needs, rather than just trying to get as much as possible.

The policy also had a positive effect on the market. High-quality generic versions of the medicine started to replace the more expensive original versions, which helped to drive down costs even further. This is a win-win situation for patients and the healthcare system as a whole.